State of the art in muscle glycogenoses

C. Angelini

Research output: Contribution to journalArticle

Abstract

The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe disease) and type V (Mc Ardle disease).

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalActa Myologica
Volume29
Issue numberOCTOBER
Publication statusPublished - Oct 2010

Fingerprint

Glycogen Storage Disease Type II
Glycogen Storage Disease
Muscles
Diet
Enzymes
Therapeutics

Keywords

  • Enzyme replacement therapy
  • Glycogenosis
  • McArdle disease
  • Pompe disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Angelini, C. (2010). State of the art in muscle glycogenoses. Acta Myologica, 29(OCTOBER), 339-342.

State of the art in muscle glycogenoses. / Angelini, C.

In: Acta Myologica, Vol. 29, No. OCTOBER, 10.2010, p. 339-342.

Research output: Contribution to journalArticle

Angelini, C 2010, 'State of the art in muscle glycogenoses', Acta Myologica, vol. 29, no. OCTOBER, pp. 339-342.
Angelini C. State of the art in muscle glycogenoses. Acta Myologica. 2010 Oct;29(OCTOBER):339-342.
Angelini, C. / State of the art in muscle glycogenoses. In: Acta Myologica. 2010 ; Vol. 29, No. OCTOBER. pp. 339-342.
@article{41db51f5ea6c4c33937e13444de6e574,
title = "State of the art in muscle glycogenoses",
abstract = "The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe disease) and type V (Mc Ardle disease).",
keywords = "Enzyme replacement therapy, Glycogenosis, McArdle disease, Pompe disease",
author = "C. Angelini",
year = "2010",
month = "10",
language = "English",
volume = "29",
pages = "339--342",
journal = "Acta Myologica",
issn = "1128-2460",
publisher = "Gaetano Conte Academy",
number = "OCTOBER",

}

TY - JOUR

T1 - State of the art in muscle glycogenoses

AU - Angelini, C.

PY - 2010/10

Y1 - 2010/10

N2 - The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe disease) and type V (Mc Ardle disease).

AB - The recognition of a series of metabolic/enzymatic dysfunctions in glycogenoses has allowed new therapeutic advances for their treatment due to the development of recombinant enzyme. A recent advance appears enzymatic replacement therapy (ERT) in glycogenosis type II in both infantile, juvenile and adult form. Targeted manipulation of diet has been tried both in glycogenosis type II (Pompe disease) and type V (Mc Ardle disease).

KW - Enzyme replacement therapy

KW - Glycogenosis

KW - McArdle disease

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=78651432253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651432253&partnerID=8YFLogxK

M3 - Article

C2 - 21314016

AN - SCOPUS:78651432253

VL - 29

SP - 339

EP - 342

JO - Acta Myologica

JF - Acta Myologica

SN - 1128-2460

IS - OCTOBER

ER -